This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
More

Throughout the year, Novo Nordisk research is presented at several major congresses. We welcome you to explore the Novo Nordisk sponsored science that is presented using ScienceHub, which gives you free access to a comprehensive collection of digital features extending the official congress materials. The materials include audio poster tours, infographics, podcasts, videos featuring our presenters and supplementary slide decks.

Rounding off 2021, Novo Nordisk research was featured at the congress of the International Diabetes Federation (IDF) , which took place as a virtual event in the beginning of December. The IDF congress is held every two years, offering a forum to exchange and develop insights into a wide spectrum of diabetes-related topics. There is a core focus on the latest scientific advances in diabetes care and beyond, and other recurrent themes include efforts to improve diabetes education and awareness.

This year, the Novo Nordisk-related presentations focused mostly on the real-world use of the combination of insulin degludec and insulin aspart.